Results of the 2nd scientific workshop of the ECCO (IV): Therapeutic strategies to enhance intestinal healing in inflammatory bowel disease

Pariente, 2011, Development of the Crohn's disease digestive damage score, the Lémann score, Inflamm Bowel Dis, 17, 1415, 10.1002/ibd.21506 Frøslie, 2007, Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort, Gastroenterology, 133, 412, 10.1053/j.gastro.2007.05.051 Solberg, 2008, Mucosal healing after initial treatment may be a prognostic marker for long-term outcome in inflammatory bowel disease, Gut, 57, A-15 Baert, 2010, Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease, Gastroenterology, 138, 463, 10.1053/j.gastro.2009.09.056 D'Haens, 2002, Endoscopic healing after infliximab treatment for Crohn's disease provides a longer time to relapse, Gastroenterology, 122, A100 Rutgeerts, 2006, Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease, Gastrointest Endosc, 63, 433, 10.1016/j.gie.2005.08.011 Schnitzler, 2009, Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease, Inflamm Bowel Dis, 15, 1295, 10.1002/ibd.20927 Colombel, 2010, Adalimumab treatment results in deep remission for patients with moderate to severe ileocolonic Crohn's disease: results from EXTEND, Gastroenterology, 138, S518 Wright, 1966, Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets, Am J Dig Dis, 11, 847, 10.1007/BF02233941 Meucci, 2006, Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: preliminary results of a prospective, multicenter study, Gastroenterology, 130, A197 Kamm, 2008, Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis, Gut, 57, 893, 10.1136/gut.2007.138248 Ferrante, 2008, Long-term outcome after infliximab for refractory ulcerative colitis, J Crohns Colitis, 2, 219, 10.1016/j.crohns.2008.03.004 Colombel, 2011, Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis, Gastroenterology, 141, 1194, 10.1053/j.gastro.2011.06.054 Sandborn, 2002, A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease, Gastroenterology, 122, 512, 10.1053/gast.2002.31072 D'Haens, 2007, A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis, Gastroenterology, 132, 763, 10.1053/j.gastro.2006.12.038 Mary, 1989, Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID), Gut, 30, 983, 10.1136/gut.30.7.983 Daperno, 2004, Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD, Gastrointest Endosc, 60, 505, 10.1016/S0016-5107(04)01878-4 Rutgeerts, 1990, Predictability of the postoperative course of Crohn's disease, Gastroenterology, 99, 956, 10.1016/0016-5085(90)90613-6 Schroeder, 1987, Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study, N Engl J Med, 317, 1625, 10.1056/NEJM198712243172603 Baron, 1964, Variation between observers in describing mucosal appearances in proctocolitis, BMJ, 1, 89, 10.1136/bmj.1.5375.89 Sands, 2005, Design issues and outcomes in IBD clinical trials, Inflamm Bowel Dis, 11, S22, 10.1097/01.MIB.0000184849.38816.39 Pineton de Chambrun, 2010, Clinical implications of mucosal healing for the management of IBD, Nat Rev Gastroenterol Hepatol, 7, 15, 10.1038/nrgastro.2009.203 Lichtenstein, 2010, Importance of mucosal healing in ulcerative colitis, Inflamm Bowel Dis, 16, 338, 10.1002/ibd.20997 Targan, 1997, A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group, N Engl J Med, 337, 1029, 10.1056/NEJM199710093371502 Colombel, 2010, Infliximab, azathioprine, or combination therapy for Crohn's disease, N Engl J Med, 362, 1383, 10.1056/NEJMoa0904492 Rutgeerts, 2009, Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic Crohn's disease — first results of the extend trial, Gastroenterology, 136, A116 Sandborn, 2007, MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials, Aliment Pharmacol Ther, 26, 205, 10.1111/j.1365-2036.2007.03361.x Rutgeerts, 2005, Infliximab for induction and maintenance therapy for ulcerative colitis, N Engl J Med, 353, 2462, 10.1056/NEJMoa050516 Reinisch, 2011, Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial, Gut, 60, 780, 10.1136/gut.2010.221127 Panaccione, 2011, Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis, Gastroenterology, 140, S134, 10.1016/S0016-5085(11)60548-9 Simren, 2002, Quality of life in inflammatory bowel disease in remission: the impact on IBS-like symptoms an associated psychological factors, Am J Gastroenterol, 97, 389, 10.1016/S0002-9270(01)04037-0 Louis, 2012, Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped, Gastroenterology, 142, 63, 10.1053/j.gastro.2011.09.034 Landi, 1992, Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives, Gastroenterology, 102, 1647, 10.1016/0016-5085(92)91725-J Present, 1989, 6-Mercaptopurine and other immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis, Gastroenterol Clin North Am, 18, 57, 10.1016/S0889-8553(21)00426-X D'Haens, 1997, Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease, Gastroenterology, 112, 1475, 10.1016/S0016-5085(97)70027-1 D'Haens, 1999, Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine, Gastrointest Endosc, 50, 667, 10.1016/S0016-5107(99)80017-0 Modigliani, 1990, Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives, Gastroenterology, 98, 811, 10.1016/0016-5085(90)90002-I Olaison, 1990, Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation, Gut, 31, 325, 10.1136/gut.31.3.325 Mantzaris, 2009, Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease, Inflamm Bowel Dis, 15, 375, 10.1002/ibd.20777 Lémann, 2005, Groupe D'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine, Gastroenterology, 128, 1812, 10.1053/j.gastro.2005.03.031 D'Haens, 2008, Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial, Lancet, 371, 660, 10.1016/S0140-6736(08)60304-9 Reinisch, 2010, Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial, Gut, 59, 752, 10.1136/gut.2009.194159 Kozarek, 1989, Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease, Ann Intern Med, 110, 353, 10.7326/0003-4819-110-5-353 Feagan, 1995, Methotrexate for the treatment of Crohn's disease, N Engl J Med, 332, 292, 10.1056/NEJM199502023320503 Feagan, 2000, A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease, N Engl J Med, 342, 1627, 10.1056/NEJM200006013422202 Laharie, 2011, Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab, Aliment Pharmacol Ther, 33, 714, 10.1111/j.1365-2036.2010.04569.x D'Haens, 1999, Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial, Gastroenterology, 116, 1029, 10.1016/S0016-5085(99)70005-3 Rutgeerts, 2004, Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease, Gastroenterology, 126, 402, 10.1053/j.gastro.2003.11.014 Hébuterne, 2008, Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: first results of the MUSIC trial, Gut, 57, A15 Sandborn, 2005, International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn's disease, N Engl J Med, 353, 1912, 10.1056/NEJMoa043335 Rutgeerts, 2004, Effects of natalizumab on gut healing in a phase 3 study of active Crohn's disease therapy (ENACT-1), Gastroenterology, 126, A-208 Zachos, 2007, Enteral nutritional therapy for induction of remission in Crohn's disease, Cochrane Database Syst Rev, 1, CD000542 Akobeng, 2007, Enteral nutrition for maintenance of remission in Crohn's disease, Cochrane Database Syst Rev, 3, CD005984 Borrelli, 2006, Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial, Clin Gastroenterol Hepatol, 4, 744, 10.1016/j.cgh.2006.03.010 Riley, 1991, Microscopic activity in ulcerative colitis: what does it mean?, Gut, 32, 174, 10.1136/gut.32.2.174 Courtney, 1991, Colonoscopic appearance in remission predicts relapse of ulcerative colitis, Gastroenterology, 100, A205 Campieri, 1981, Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas, Lancet, 2, 270, 10.1016/S0140-6736(81)90523-7 Truelove, 1955, Cortisone in ulcerative colitis. Final report on a therapeutic trial, BMJ, 2, 1041, 10.1136/bmj.2.4947.1041 Ardizzone, 2006, Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis, Gut, 55, 47, 10.1136/gut.2005.068809 Paoluzi, 2002, Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission, Aliment Pharmacol Ther, 16, 1751, 10.1046/j.1365-2036.2002.01340.x Sandborn, 2011, Induction and maintenance of clinical remission by adalimumab in patients with moderate-to-severe ulcerative colitis, J Crohns Colitis, 5, P136 Feagan, 2005, Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin, N Engl J Med, 352, 2499, 10.1056/NEJMoa042982 Markowitz, 2000, A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease, Gastroenterology, 119, 895, 10.1053/gast.2000.18144 Candy, 1995, A controlled double blind study of azathioprine in the management of Crohn's disease, Gut, 37, 674, 10.1136/gut.37.5.674 Hanauer, 2002, Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial, Lancet, 359, 1541, 10.1016/S0140-6736(02)08512-4 Hyams, 2007, Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children, Gastroenterology, 132, 863, 10.1053/j.gastro.2006.12.003 Colombel, 2007, Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial, Gastroenterology, 132, 52, 10.1053/j.gastro.2006.11.041 Hyams, 2011, Induction and maintenance adalimumab therapy for the treatment of moderate to severe Crohn's disease in children, J Crohn's Colitis, 5, S5 Colombel, 2010, Effect of disease duration on “deep remission”: results from the Extend trial, Gut, 59, A188 Goekoop-Ruiterman, 2005, Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial, Arthritis Rheum, 52, 3381, 10.1002/art.21405 Goekoop-Ruiterman, 2007, Comparison of treatment strategies in early rheumatoid arthritis a randomized trial, Ann Intern Med, 146, 406, 10.7326/0003-4819-146-6-200703200-00005 Regueiro, 2006, Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials, Inflamm Bowel Dis, 12, 979, 10.1097/01.mib.0000231495.92013.5e Marteau, 2005, Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study, Gut, 54, 960, 10.1136/gut.2004.060103 Treton, 2009, Groupe D'Etude Thérapeutique Des Affections Inflammatoires Du Tube Digestif (GETAID). Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse, Clin Gastroenterol Hepatol, 7, 80, 10.1016/j.cgh.2008.08.028 Cassinotti, 2009, Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal, Am J Gastroenterol, 104, 2760, 10.1038/ajg.2009.410